Daclizumab is a monoclonal antibody medication used to treat relapsing remitting multiple sclerosis (RRMS). It is administered intravenously and works by targeting a specific type of white blood cell, known as a lymphocyte, that plays a role in the body's inflammatory response. Daclizumab works by binding to the CD25 antigen on the surface of the lymphocytes and preventing them from entering the central nervous system, which helps to reduce the risk of relapse in people with RRMS. Additionally, this medication has been found to reduce the rate of brain atrophy and number of new brain lesions in those with RRMS.
Daclizumab, previously sold under the brand name Zinbryta, was a medication used for a specific purpose but is no longer available due to safety concerns [1, 5]. Here's a closer look at its past use and withdrawal:
What it was for:
- Daclizumab was a humanized monoclonal antibody used to treat adults with relapsing forms of multiple sclerosis (MS) [1, 2]. MS is an autoimmune disease that affects the central nervous system.
- It functioned by targeting the interleukin-2 receptor (IL-2R) on T cells, a type of immune cell [2]. By blocking this receptor, Daclizumab aimed to modulate the immune response and potentially reduce relapses in MS patients.
Why it's no longer available:
- Daclizumab was voluntarily withdrawn from the market in March 2018 due to reports of serious side effects, including autoimmune encephalitis (inflammation of the brain) [3, 5].
- The potential benefits of Daclizumab were deemed to be outweighed by the risks of these severe side effects [5].
Additional information:
- Daclizumab was administered subcutaneously (injected under the skin) typically once a month [2].
- There were ongoing discussions about the potential risks and benefits of Daclizumab before its withdrawal [4].
Current MS treatment options:
- Several other medications are available for treating relapsing forms of MS. If you have MS, consult a healthcare professional to discuss the most appropriate treatment options for your specific case.
Disclaimer: I cannot provide medical advice. This information about Daclizumab is for informational purposes only.